Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

2.44
+0.01000.41%
Post-market: 2.20-0.2400-9.84%19:55 EDT
Volume:83.88K
Turnover:198.93K
Market Cap:13.02M
PE:-0.09
High:2.44
Open:2.44
Low:2.34
Close:2.43
52wk High:28.61
52wk Low:1.79
Shares:5.34M
Float Shares:4.89M
Volume Ratio:0.68
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-28.4200
EPS(LYR):-158.0236
ROE:-256.05%
ROA:-80.35%
PB:0.87
PE(LYR):-0.02

Loading ...

Moleculin Biotech Inc - Reports 40% Preliminary Crc Rate in Miracle Trial

THOMSON REUTERS
·
Feb 18

Moleculin Biotech Inc - Expects Recruitment of First 45 Subjects by Q1 2026

THOMSON REUTERS
·
Feb 18

Moleculin MIRACLE trial reports 40% preliminary blinded CRc rate in relapsed or refractory AML

Reuters
·
Feb 18

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

THOMSON REUTERS
·
Feb 17

Moleculin Biotech Receives Notice of Allowance for Japanese Patent Covering Liposomal Annamycin

Reuters
·
Feb 17

Moleculin Biotech Inc. Launches CEO Corner to Enhance Stakeholder Communication and Outlines Plans to Advance Lead Clinical Programs and Pipeline Development

Reuters
·
Feb 13

Moleculin Biotech Inc. Held Special Stockholder Meeting

Reuters
·
Feb 06

Moleculin Biotech nimmt an virtueller Corporate-Connect-Konferenz von Webull Financial teil

Reuters
·
Feb 05

BUZZ-Moleculin Biotech rises as cancer drug shows no heart damage in trials

Reuters
·
Jan 13

Moleculin Biotech Reports Annamycin Shows No Cardiotoxicity in 90 Clinical Trial Subjects

Reuters
·
Jan 13

BRIEF-Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding On Track, Global Trial Expansion, And Multiple Externally/Iit Funded Clinical Programs

Reuters
·
Jan 12

Moleculin Biotech Inc - First Miracle Trial Unblinding Expected Q1 2026; Global Trial NOW Spans Nine Countries

THOMSON REUTERS
·
Jan 12

Moleculin Biotech Inc - Primary Efficacy Data for Miracle Expected in 2028

THOMSON REUTERS
·
Jan 12

BRIEF-Moleculin Biotech Regains Nasdaq Listing Compliance

Reuters
·
Jan 07

Moleculin Biotech Inc - Regains Nasdaq Listing Compliance - SEC Filing

THOMSON REUTERS
·
Jan 07

Moleculin Biotech Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Dec 20, 2025

Moleculin Reports Positive Phase 1 Results for WP1066 in Pediatric Brain Tumors

Reuters
·
Dec 17, 2025

Moleculin Biotech Inc - WP1066 Found Safe and Effective, Warranting Phase 2 Trial

THOMSON REUTERS
·
Dec 17, 2025

Moleculin Announces Positive Results From Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

THOMSON REUTERS
·
Dec 17, 2025

Moleculin Biotech Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 11, 2025